atorvastatin has been researched along with phenyl acetate in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alegret, M; Díaz, C; Hernández, G; Jové, M; Laguna, JC; Llaverías, G; Sánchez, RM; Vázquez-Carrera, M | 1 |
| Heinonen, T; Klepack, E; Lovalvo, J; Marais, AD; McLain, R; Raal, FJ | 1 |
| Budoff, MJ; Gao, YL; Kessler, P; Mao, SS; Moustafa, M; Qunibi, W | 1 |
| Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG | 1 |
| Budoff, M; Diaz-Buxo, JA; He, DY; Kessler, PD; Moustafa, M; Muenz, LR; Qunibi, W | 1 |
| Cheng, S; Ge, S; Liu, D; Liu, X; Xu, G; Xu, J; Zhou, G | 1 |
| Cheng, S; Ge, S; Liu, D; Liu, X; Liu, Z; Xu, G; Zhang, R; Zhou, G; Zhu, W | 1 |
| Elliott, M; Goulder, M; Hislop, C; Rosenson, RS; Stasiv, Y; Waters, D | 1 |
| Rosenson, RS | 1 |
| Fraser, H; Goulder, MA; Hislop, C; Rosenson, RS | 1 |
| Bash, D; Cavender, MA; Hislop, C; Kastelein, JJ; Nicholls, SJ; Rosenson, RS; Schwartz, G; Waters, DD | 1 |
| Choi, YJ; Geaney, JC; Karpf, DB; Krauss, RM; Naim, S; Roberts, BK; Wang, X; Wojnoonski, K | 1 |
| Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS | 1 |
| Bjorndahl, TC; Caplice, NM; Fitzgerald, GF; London, LE; Mandal, R; Murphy, K; Ross, RP; Ryan, PM; Shanahan, F; Stanton, C; Wishart, DS | 1 |
| Adedoyin, A; Cho, CR; Fox-Bosetti, S; Iwamoto, M; Liu, F; Macha, S; McCrea, JB; Menzel, K; Panebianco, D; Stoch, SA; Zhao, T | 1 |
9 trial(s) available for atorvastatin and phenyl acetate
| Article | Year |
|---|---|
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Age Factors; Atorvastatin; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Sex Factors; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids; Treatment Outcome | 2003 |
The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study.
Topics: Acetates; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Reproducibility of Results; Sevelamer; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.
Topics: Acetates; Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Renal Dialysis; Sevelamer; Time Factors | 2008 |
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
Topics: Acetates; Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Prospective Studies; Pyrroles; Reference Values; Treatment Outcome | 2010 |
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Topics: Acetates; Acute Coronary Syndrome; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles | 2011 |
Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
Topics: Acetates; Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-6; Keto Acids; Male; Middle Aged; Pyrroles; Treatment Outcome | 2011 |
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
Topics: Acetates; Acute Coronary Syndrome; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Keto Acids; Phospholipases A2, Secretory; Pyrroles | 2012 |
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
Topics: Acetates; Analysis of Variance; Atherosclerosis; Atorvastatin; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Obesity; Overweight; Particle Size; PPAR gamma; Pyrroles; Time Factors; Treatment Outcome; Triazoles | 2012 |
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome | 2014 |
6 other study(ies) available for atorvastatin and phenyl acetate
| Article | Year |
|---|---|
Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages.
Topics: Acetamides; Acetates; Atorvastatin; Cells, Cultured; Cholesterol Esters; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Pyrroles; Sulfonamides; Sulfonic Acids | 2002 |
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Topics: Acetamides; Acetates; Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Pyrroles; Rabbits; Random Allocation; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2007 |
Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.
Topics: Acetates; Animals; Atherosclerosis; Atorvastatin; Carotid Arteries; Catheterization; Chemokine CCL2; Cyclopropanes; Diet, Atherogenic; Disease Progression; Heptanoic Acids; Immunohistochemistry; Leukotriene Antagonists; Lipids; Male; Pyrroles; Quinolines; Rabbits; Random Allocation; Sulfides | 2009 |
Montelukast inhibits matrix metalloproteinases expression in atherosclerotic rabbits.
Topics: Acetates; Animals; Atherosclerosis; Atorvastatin; Cyclopropanes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukotriene Antagonists; Lipids; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocytes, Smooth Muscle; Pyrroles; Quinolines; Rabbits; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; Sulfides | 2009 |
Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E
Topics: Acetates; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; beta-Glucans; Butyrates; Cardiovascular Diseases; Carnitine; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Dietary Supplements; Feces; Gastrointestinal Microbiome; Hemiterpenes; Limosilactobacillus reuteri; Male; Metabolome; Mice; Obesity; Pentanoic Acids; Probiotics | 2017 |
Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants.
Topics: Acetates; Adult; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Interactions; Female; Healthy Volunteers; Humans; Neoplasm Proteins; Quinazolines | 2022 |